Theravance Biopharma (TBPH) Gross Margin (2013 - 2018)
Theravance Biopharma (TBPH) posted quarterly Gross Margin of 95.98% for Q4 2018, up 4693.0% year-over-year from 2.0% in Q4 2017, and up 1.56% quarter-over-quarter from 94.51% in Q3 2018.
Powered by 
Analysis
Theravance Biopharma (TBPH) Gross Margin (2013 - 2018) Analysis & Trends
Theravance Biopharma (TBPH) has reported Gross Margin for 6 consecutive years, with 95.98% the latest figure, recorded in Q4 2018.
- In Q4 2018, Gross Margin rose 4693.0% year-over-year to 95.98%; the TTM figure through Dec 2018 stood at 94.02% (up 2791.0% YoY), while the FY2018 annual figure was 98.82%, up 3801.0% from the prior year.
- Gross Margin advanced to 95.98% in Q4 2018 per TBPH's latest filing, from 94.51% in the prior quarter.
- Across five years, Gross Margin topped out at 98.26% in Q3 2016 and bottomed at 124.84% in Q4 2014.
- Historically, Gross Margin has averaged 72.82% across 5 years, with a median of 91.77% in 2014.
- Annual changes were most pronounced in 2014 — Gross Margin plunged 22484 bps — and 2015, when it jumped 14262 bps.
- Theravance Biopharma's Gross Margin stood at 124.84% in 2014, then jumped by 114 bps to 17.78% in 2015, then surged by 349 bps to 79.87% in 2016, then plunged by 39 bps to 49.06% in 2017, then soared by 96 bps to 95.98% in 2018.
- Business Quant data shows TBPH's Gross Margin at 95.98% in Q4 2018, 94.51% in Q3 2018, and 93.83% in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 95.98% |
| Sep 30, 2018 | 94.51% |
| Jun 30, 2018 | 93.83% |
| Mar 31, 2018 | 90.07% |
| Dec 31, 2017 | 49.06% |
| Sep 30, 2017 | 76.96% |
| Jun 30, 2017 | 61.13% |
| Mar 31, 2017 | 81.70% |
| Dec 31, 2016 | 79.87% |
| Sep 30, 2016 | 98.26% |
| Jun 30, 2016 | 95.75% |
| Mar 31, 2016 | 95.77% |
| Dec 31, 2015 | 17.78% |
| Sep 30, 2015 | 94.57% |
| Jun 30, 2015 | 92.92% |
| Mar 31, 2015 | 98.18% |
| Dec 31, 2014 | -124.84% |
| Sep 30, 2014 | 94.18% |
| Jun 30, 2014 | 90.62% |
| Mar 31, 2014 | 80.11% |